[HTML][HTML] Targeting antigen to the surface of EVs improves the in vivo immunogenicity of human and non-human adenoviral vaccines in mice
CM Bliss, AJ Parsons, R Nachbagauer… - … Therapy-Methods & …, 2020 - cell.com
Adenoviral (Ad) vectors represent promising vaccine platforms for infectious disease. To
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …
Targeting antigen to the surface of EVs improves the in vivo immunogenicity of human and non-human adenoviral vaccines in mice
CM Bliss, AJ Parsons, R Nachbagauer… - … Therapy-Methods and …, 2020 - orca.cardiff.ac.uk
Adenoviral (Ad) vectors represent promising vaccine platforms for infectious disease. To
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …
[HTML][HTML] Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice
CM Bliss, AJ Parsons, R Nachbagauer… - … Therapy-Methods & …, 2020 - Elsevier
Adenoviral (Ad) vectors represent promising vaccine platforms for infectious disease. To
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …
[引用][C] Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice
CM Bliss, AJ Parsons, R Nachbagauer… - … Therapy-Methods & …, 2020 - cir.nii.ac.jp
Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and
Non-human Adenoviral Vaccines in Mice | CiNii Research CiNii 国立情報学研究所 学術情報 …
Non-human Adenoviral Vaccines in Mice | CiNii Research CiNii 国立情報学研究所 学術情報 …
Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice
CM Bliss, AJ Parsons… - … therapy. Methods & …, 2019 - pubmed.ncbi.nlm.nih.gov
Adenoviral (Ad) vectors represent promising vaccine platforms for infectious disease. To
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …
[HTML][HTML] Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice
CM Bliss, AJ Parsons, R Nachbagauer… - … Therapy. Methods & …, 2020 - ncbi.nlm.nih.gov
Adenoviral (Ad) vectors represent promising vaccine platforms for infectious disease. To
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …
[PDF][PDF] Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice
CM Bliss, AJ Parsons, R Nachbagauer… - Molecular …, 2020 - scienceopen.com
Adenoviral (Ad) vectors represent promising vaccine platforms for infectious disease. To
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …
Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice.
CM Bliss, AJ Parsons, R Nachbagauer… - … therapy. Methods & …, 2019 - europepmc.org
Adenoviral (Ad) vectors represent promising vaccine platforms for infectious disease. To
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …
[PDF][PDF] Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice
CM Bliss, AJ Parsons, R Nachbagauer, JR Hamilton… - Molecular …, 2020 - core.ac.uk
Adenoviral (Ad) vectors represent promising vaccine platforms for infectious disease. To
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …
Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice.
CM Bliss, AJ Parsons, R Nachbagauer… - … therapy. Methods & …, 2019 - europepmc.org
Adenoviral (Ad) vectors represent promising vaccine platforms for infectious disease. To
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …